Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureBüşra Aydur Püren, Semra Usta, Yavuz Sami Salihoğlu, Rabiye Uslu Erdemir
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Histological type and typing of breast carcinomas and the WHO classification changes over time
10.32074/1591-951x-1-20 · 2020
Biological subtypes of breast cancer: prognostic and therapeutic implica-tions
10.5306/wjco.v5.i3.412 · 2014
10.1016/j.molonc.2010.04.004
10.1016/j.molonc.2010.04.004
Tumor heterogeneity: causes and consequences
10.1016/j.bbcan.2009.11.002 · 2010
10.1016/s0140-6736(11)60993-8
10.1016/s0140-6736(11)60993-8
10.1371/journal.pone.0021030
10.1371/journal.pone.0021030
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
10.1093/annonc/mdz173 · 2019
10.31590/ejosat.780052
10.31590/ejosat.780052
Radiomics: extracting more information from medical images using advanced feature analysis
10.1016/j.ejca.2011.11.036 · 2012
Overview of radiomics in breast cancer diagnosis and prognostication
10.1016/j.breast.2019.10.018 · 2020
Quantitative FDG PET Assessment for oncology therapy
10.3390/cancers13040869 · 2021
Estrogen and proges-terone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
10.5858/arpa.2019-0904-sa · 2020
Human epidermal growth factor receptor 2 testing in breast cancer: American So-ciety of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Fo-cused Update
10.5858/arpa.2018-0902-sa · 2018
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
10.1093/annonc/mdt303 · 2013
LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity
10.1158/0008-5472.can-18-0125 · 2018
the image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping
10.1148/radiol.2020191145 · 2020
PET radi-omics signatures and artificial intelligence for decoding immunotherapy response in advanced cutaneous squamous cell carcinoma: a retrospective single-center study
10.3390/app15126453 · 2025
Joint EANM/SNMMI guideline on radiomics in nuclear medicine : Jointly supported by the EANM Physics Committee and the SNMMI Physics, Instrumentation and Data Sciences Council
10.1007/s00259-022-06001-6 · 2023
10.1371/journal.pone.0145063
10.1371/journal.pone.0145063
Radiomics in breast cancer classification and prediction
10.1016/j.semcancer.2020.04.002 · 2021
Unresolved referenced work
Kept as external metadata until matched
Metabolic radiomics for pretreatment 18F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neo-adjuvant chemotherapy, and prognosis
10.1038/s41598-017-01524-7 · 2017
[18F]FDG PET/CT features for the molecular characterization of primary breast tumors
10.1007/s00259-017-3770-9 · 2017
Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer
10.1007/s00259-017-3830-1 · 2018
10.4274/mirt.galenos.2022.59140
10.4274/mirt.galenos.2022.59140
Comparison of the volumetric and radiomics findings of 18F-FDG PET/CT images with immunohistochemical prognostic factors in local/locally advanced breast cancer
10.1097/mnm.0000000000001019 · 2019
10.1371/journal.pone.0094017
10.1371/journal.pone.0094017
Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and tex-tural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
10.1007/s00259-017-3641-4 · 2017
Prediction of HER2 expression in breast can-cer by combining PET/CT radiomic analysis and machine learning
10.1007/s12149-021-01688-3 · 2022
Glucose metabolism in cancer: the warburg effect and beyond
10.1007/978-3-030-65768-0_1 · 2021
The biological roles and clinical applications of the PI3K/AKT pathway in targeted therapy resistance in HER2-Positive breast cancer: a comprehensive review
10.3390/ijms252413376 · 2024
Targeting mTOR and glycolysis in HER2-positive breast cancer
10.3390/cancers13122922 · 2021
Association between 18F-FDG uptake and molecular subtype of breast cancer
10.1007/s00259-015-3070-1 · 2015
No additional external references are available.